Clinical trials
Respiratory Syncytial Virus (RSV) clinical trials
Below are recruiting respiratory syncytial virus (rsv) clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06873633RecruitingPhase 2
Testing remdesivir for RSV in hospitalized children under 2
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
BangkokAges birth–2 years - NCT06881953Recruiting
Preventing RSV in infants in France
This trial studies ways to prevent RSV infections in newborns. If you are a parent who gave birth in France between October 2024 and January 2025, you may be able to help researchers learn how to better protect babies from RSV.
ParisAges 18 years+ - NCT06998251Recruiting
Immune response to strep pneumonia in older adults
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
GenevaAges 60–85 - NCT07239583Recruiting
RSV infection and health impact in older adults in Vietnam
This study looks at how common RSV (a virus that can cause serious breathing problems) is in older adults who are hospitalized with respiratory symptoms or worsening heart/lung conditions. By joining, you help researchers understand the virus and improve care for people your age.
Ho Chi Minh City, Southern VietnamAges 60 years+ - NCT06363370RecruitingPhase 3
Interferon inhalation for RSV in children under 2
This trial tests if an inhaled interferon solution can help children under 2 years old with a moderate to severe RSV lung infection. It aims to reduce symptoms like cough and trouble breathing.
Beijing, Beijing MunicipalityAges 2 months–2 years - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75 - NCT07516418RecruitingPhase 1
RSV and Flu H5 Vaccine Formulations Study
This study tests different versions of experimental vaccines designed to protect against RSV (a common respiratory virus) and flu H5. You'll receive one of these vaccines and be monitored to see how safe it is and how your body responds.
Griffith, QueenslandAges 18–49 - NCT07582796RecruitingPhase 1/Phase 2
RSV Vaccine Study for Adults in China
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
Zigong, SichuanAges 18 years+ - NCT07658534RecruitingPhase 2/Phase 3
Ziresovir for high-risk adults with RSV
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Beijing, Beijing MunicipalityAges 18–85 - NCT06817889RecruitingPhase 2
Remdesivir for RSV in people with weak immune systems
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
Duarte, CaliforniaAges 18 years+ - NCT07402512RecruitingPhase 3
Study of deuremidevir for RSV in infants and young children
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Xiamen, FujianAges 1 month–3 years - NCT07628049RecruitingPhase 1/Phase 2
RSV and hMPV vaccine study in younger and older adults
This study tests two investigational vaccines designed to protect against RSV (respiratory syncytial virus) and hMPV (human metapneumovirus), which are common respiratory viruses. Researchers want to see if these vaccines are safe and help the body fight these infections in adults aged 18–80.
Lenexa, KansasAges 18–80
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for respiratory syncytial virus (rsv)?
- Yes. Clin2 currently lists 36 recruiting respiratory syncytial virus (rsv) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a respiratory syncytial virus (rsv) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a respiratory syncytial virus (rsv) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.